a clinically relevant drug in PMs. PMscontaining mithramycin were prepared and tested in vitro as a therapeutic protocol forbeta-thalassemia.In conclusion, the results of this study had demonstrated that microfluidics couldfacilitate the production of nanostructures for drug delivery purposes, and offer anovel method to control their properties including particle size, size distribution andpharma